Product
TYSABRI
1 clinical trial
1 indication
Indication
Relapsing-remitting multiple sclerosisClinical trial
Optical Coherence Tomography as a Measure of Neuroprotection in Patients With Relapsing-Remitting Multiple Sclerosis Receiving Natalizumab or Interferon Beta-1aStatus: Withdrawn, Estimated PCD: 2009-08-01